Tyrosine News and Research

RSS

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

Phase 1 clinical studies of the experimental anticancer drug lenvatinib indicate that it may achieve at least a partial response in thyroid, endometrial, and renal cancers and melanoma.

28 Oct 2011

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

BeiGene, Ltd., today announced that it has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV and its affiliates for two clinical-stage oncology compounds.

15 Oct 2011

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers - combine them with inhibitors of the MEK/ERK signaling pathway.

11 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

Fat-rich 'western diet' fuels cardiovascular disease, type 2 diabetes and obesity

A major risk factor for cardiovascular disease, type 2 diabetes and other health- and life-threatening conditions, obesity is epidemic in the United States and other developed nations where it's fueled in large part by excessive consumption of a fat-rich "Western diet."

30 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Study reveals possible new treatment targets for diffuse intrinsic pontine gliomas

Study led by St. Jude Children's Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.

21 Sep 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 - 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.

3 Sep 2011

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

University of Florida researchers have modified a toxic chemical produced by tiny marine microbes and successfully deployed it against laboratory models of colon cancer.

2 Sep 2011

Insight into acrolein-induced acute lung injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Integrative Metabolome and Transcriptome Profiling Reveals Discordant Energetic Stress Between Mouse Strains with Differential Sensitivity to Acrolein-Induced Acute Lung Injury" in The Molecular Nutrition and Food Research Journal.

24 Aug 2011

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

NCI, Pharmacyclics sign CRADA to develop PCI-32765 for blood cancers

Pharmacyclics, Inc. today announced the signing of a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765, a first-in-class, small molecule inhibitor of Bruton's tyrosine kinase (Btk) for the treatment of hematologic malignancies.

10 Aug 2011

ArQule second quarter net loss increases to $10,804,000

ArQule, Inc. today announced its financial results for the second quarter of 2011.

4 Aug 2011

Conference to discuss novel studies that address how inherited genes cause breast cancer

A woman's ethnicity as well as her genetic makeup are two of the main risk factors for hereditary breast cancer. Research into understanding and treating hereditary breast cancer will be presented today at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.